Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$22.80 USD

22.80
820,436

+0.59 (2.66%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $22.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CORT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Corcept Therapeutics Incorporated falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 368 432 224 441 276
Receivables 41 31 28 26 20
Notes Receivable 0 0 0 0 0
Inventories 8 6 5 5 5
Other Current Assets 42 30 10 7 6
Total Current Assets 459 499 266 479 307
Net Property & Equipment 0 1 1 2 1
Investments & Advances 57 5 112 36 39
Other Non-Current Assets 8 11 13 16 12
Deferred Charges 91 61 27 32 46
Intangibles 0 0 0 0 0
Deposits & Other Assets 7 5 3 5 3
Total Assets 622 583 424 572 412
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 17 12 7 11 8
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 87 45 40 35 30
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 14 0 0 2
Total Current Liabilities 105 72 48 47 39
Mortgages 0 0 0 0 0
Deferred Taxes/Income 10 9 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 115 82 48 48 41
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 739 662 591 516 457
Retained Earnings 403 296 195 82 -24
Other Equity 1 -1 0 0 0
Treasury Stock 635 456 410 76 63
Total Shareholder's Equity 507 502 376 523 371
Total Liabilities & Shareholder's Equity 622 583 424 572 412
Total Common Equity 507 502 376 523 371
Shares Outstanding 103.00 107.60 115.40 116.10 114.20
Book Value Per Share 4.92 4.66 3.26 4.51 3.25

Fiscal Year End for Corcept Therapeutics Incorporated falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 368 355 363 465
Receivables NA 41 35 33 33
Notes Receivable NA 0 0 0 0
Inventories NA 8 8 7 6
Other Current Assets NA 42 34 30 30
Total Current Assets NA 459 432 433 534
Net Property & Equipment NA 0 0 0 0
Investments & Advances NA 57 60 0 0
Other Non-Current Assets NA 8 9 9 10
Deferred Charges NA 91 87 78 68
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 7 7 4 5
Total Assets NA 622 594 525 618
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 17 17 8 11
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 87 91 71 53
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 14 14 14
Total Current Liabilities NA 105 122 93 79
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 10 10 10 9
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 115 132 103 88
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 739 722 696 680
Retained Earnings NA 403 371 340 312
Other Equity NA 1 0 0 0
Treasury Stock NA 635 632 614 463
Total Shareholder's Equity NA 507 462 422 530
Total Liabilities & Shareholder's Equity NA 622 594 525 618
Total Common Equity 0 507 462 422 530
Shares Outstanding 103.50 103.00 103.00 102.50 101.50
Book Value Per Share 0.00 4.92 4.48 4.11 5.22